ClinicalTrials.gg

TargetBeta

PDCD1

programmed cell death 1 · also CD279, PD1, hSLE1, PD-1 · CD molecules

54 programs in company-led studies act on PDCD1, from 41 companies: 28 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (41 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
pembrolizumabruleMerckphase 418743 running–ChEMBL
NivolumabruleBristol-Myers Squibbphase 416317 running–ChEMBL
dostarlimabruleGlaxoSmithKlinephase 42617 running–ChEMBL
toripalimabruleRemeGenphase 43316 running–ChEMBL
ivonescimabruleAkesophase 34839 runningVEGFANCIt
rilvegostomigAstraZenecaphase 32423 runningTIGITa judged reading
cadonilimabruleAkesophase 34522 runningCTLA4NCIt
tislelizumabruleBeOne Medicinesphase 37420 running–ChEMBL
cemiplimabruleRegeneron Pharmaceuticalsphase 34218 running–ChEMBL
volrustomigAstraZenecaphase 31917 runningCTLA4a judged reading
tivunatamigPfizerphase 31515 runningVEGFAthe company's pipeline
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 32214 runningCTLA4NCIt
sintilimabruleInnovent Biologicsphase 34013 running–NCIt
serplulimabruleFosun Pharmaphase 32713 running–NCIt
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 31513 runningTIGITNCIt
camrelizumabruleJiangsu HengRui Medicinephase 35411 running–ChEMBL
enlonstobartruleCSPC Pharmaceutical Groupphase 31511 running–NCIt
zimberelimabruleGuangzhou Gloria Biosciencesphase 32010 running–NCIt
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 31010 running–NCIt
penpulimabruleSino Biopharmaceuticalphase 3279 running–NCIt
pembrolizumab, berahyaluronidase alfa drug combinationruleMerckphase 387 running–NCIt
pucotenlimabruleTaizhou Hanzhong biomedicalphase 3156 running–NCIt
balstilimabruleAgenusphase 3103 running–NCIt
rulonilimabruleLunan Pharmaceutical Groupphase 393 running–NCIt
Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890ruleIncytephase 333 runningTGFB1NCIt
Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410ruleL & L Bio Co., Ltd., Ningbo, Chinaphase 333 runningHAVCR2NCIt
ezabenlimabBoehringer Ingelheimphase 3132 running–the company's pipeline
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 342 runningTGFB1the company's pipeline
ABBV-1480RemeGenphase 322 runningVEGFAthe company's pipeline
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 322 runningVEGFANCIt
sasanlimabPfizerphase 341 running–the company's pipeline
atigotatugBristol-Myers Squibbphase 321 running–a judged reading
Anti-PD-1/IL-15 Fusion Protein JMT108ruleCSPC Pharmaceutical Groupphase 266 running–NCIt
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 244 runningVEGFAa judged reading
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 244 runningVEGFANCIt
Anti-HER2/Anti-PD-1 Bispecific Antibody SSGJ-705rule3SBiophase 243 runningERBB2NCIt
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 233 runningVEGFANCIt
Anti-PD-1/CD47 Fusion Protein HX009ruleHangzhou Hanx Biopharmaceuticalsphase 252 runningCD47NCIt
Anti-PD-1/LAG-3 Bispecific Antibody AK129ruleAkesophase 242 runningLAG3NCIt
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010ruleHC Biopharmaphase 222 runningCTLA4, VEGFANCIt
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207ruleWigen Biomedicine Technology (Shanghai)phase 222 runningVEGFANCIt
Daxokafusp AlfaSanofiphase 222 runningIL15, IL2the company's pipeline
lorigerlimabruleMacroGenicsphase 241 runningCTLA4NCIt
SHR-3045Jiangsu HengRui Medicinephase 231 running–the company's pipeline
Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317ruleBioNTechphase 211 runningENTPD1NCIt
Anti-PD-1/Anti-VEGFR2 Bispecific Antibody OTP-01ruleOttimo Pharmaphase 211 runningKDRNCIt
Tumor Protease-activated Anti-PD-1/IL-2 Fusion Protein XTX501ruleXilio Developmentphase 211 running–NCIt
Alpha-PD1/IL2 Fusion Protein AWT020ruleAnwita Biosciencesphase 122 running–NCIt
Anti-PD-1/IL-2 Fusion Protein TEV-56278Teva Pharmaceutical Industriesphase 122 runningIL2the company's pipeline
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726ruleCompass Therapeuticsphase 111 runningVEGFANCIt
Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015ruleMedigenephase 111 runningCTAG2, TNFRSF9NCIt
TQB2252Sino Biopharmaceuticalphase 111 runningLAG3the company's pipeline
eciskafusp alfaruleHoffmann-La Rochephase 120 running–NCIt
Anti-PD-1 Antibody/IL-18 Variant Immunocytokine BPT567ruleBright Peak Therapeuticsphase 110 running–NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.